Monoclonal Anti-HRSV F Antibody, Human IgG1 (Palivizumab), Unconjugated
Biozol Catalog Number:
ABS-HRF-M789-100UG
Supplier Catalog Number:
HRF-M789-100ug
Alternative Catalog Number:
ABS-HRF-M789-100UG
Manufacturer:
AcroBiosystems
Host:
Human
Category:
Antikörper
Species Reactivity:
Mouse
Conjugation:
Unconjugated
Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, singlechain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable postfusion conformation. Antibody Palivizumab, a humanized monoclonal antibody targeting the antigenic site II region of the RSV F protein. - Antikörper
Tag:
Human IgG1 | Human Kappa
Buffer:
PBS, pH7.4
Purity:
0.95
Form:
Powder
Target:
HRSV F
Immobilized HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) at 1 µg/mL (100 µL/well) can bind Monoclonal Anti-HRSV F Antibody, Human IgG1 (Palivizumab) (Cat. No. HRF-M789) with a linear range of 0.3-5 ng/mL (QC tested).
Immobilized HRSV (B) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H9) at 1 µg/mL (100 µL/well) can bind Monoclonal Anti-HRSV F Antibody, Human IgG1 (Palivizumab) (Cat. No. HRF-M789) with a linear range of 0.3-5 ng/mL (QC tested).
Monoclonal Anti-HRSV F Antibody, Human IgG1 (Palivizumab) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 0.95.
* VAT and and shipping costs not included. Errors and price changes excepted
